GW Pharma’s cannabidiol gains EC approval
April 21, 2021Research and Development EC, EU, cannabis
GW Pharmaceuticals has received European Commission (EC) approval for the type II variation application for Epidyolex (cannabidiol), as an adjunctive …
UK Government launches COVID-19 Antivirals Taskforce
April 21, 2021Research and Development COVID-19, UK government
A new Antivirals Taskforce has been launched by the government to identify treatments for UK patients who have been exposed …
Adagio raises $336 million to advance COVID-19 antibody
April 20, 2021Manufacturing and Production Adagio, COVID-19, Financing, covid-19 treatment, pharma, pharma news
Adagio Therapeutics has financed $336 million to support the rapid advancement of their novel ADG20 antibody for the treatment and …
Oxford University & Prenetics to collaborate on global rapid testing tech
April 20, 2021Manufacturing and Production
The University of Oxford, Prenetics Limited and the Oxford Suzhou Centre for Advanced Research (OSCAR) have signed collaboration agreements to …
Enhertu now available via Cancer Drugs Fund following NICE decision
April 20, 2021Manufacturing and Production AstraZeneca, breast cancer, oncology
AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …
Novartis multiple sclerosis treatment recommended by NICE
April 20, 2021Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news
NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …
Avacta’s COVID-19 lateral flow test gains clinical validation
April 20, 2021Manufacturing and Production COVID-19
Avacta have announced positive data from the clinical validation of its AffiDX SARS-CoV-2 antigen lateral flow test, based on a …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
April 19, 2021Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …
NICE launch ambitious five-year patient access strategy
April 19, 2021Sales and Marketing NICE
NICE has unveiled its five-year plan to speed up patients’ access to the latest and most effective treatments with increased …
Sanofi signs €414 million deal for C4XD oral IL-17A inhibitor programme
April 19, 2021Sales and Marketing Sanofi
Sanofi has signed an exclusive worldwide licensing agreement with C4X Discovery Limited for C4XD’s oral pre-clinical IL-17A inhibitor programme, which …
Sanofi multiple myeloma drug approved for second indication by EC
April 19, 2021Sales and Marketing European Commission, Sanofi, Sarclisa, pharma, pharma news
The European Commission (EC) has approved a second indication of Sanofi’s Sarclisa drug for the treatment of adult patients with …
Pfizer vaccine: Study finds increased breakthrough rates of South African variant
April 19, 2021Sales and Marketing COVID-19, Pfizer, Vaccine, variant
A study published by Tel Aviv University has found an increased breakthrough rate of the South African variant of COVID-19 …
Pharmafile.com’s top 10 news stories of the week
April 16, 2021Medical Communications covid 19 news, covid-19 news, news roundup, pharma, pharma news
A number of new COVID-19 developments have dominated the news again this week: J&J’s vaccine for the virus has been …
MHRA grants marketing authorisation for new formulation of Tysabri
April 16, 2021Medical Communications MHRA
Biogen UK has been granted marketing authorisation by the MHRA for a subcutaneous (SC) injection of Tysabri (natalizumab), for adults …
Merck cease development of $425 million COVID-19 treatment
April 16, 2021Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news
Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.
EMA to begin review of GSK and Vir’s COVID-19 treatment
April 16, 2021Medical Communications COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir
The EMA have begun a review of GSK and Vir Biotechnology’s investigational COVID-19 antibody (VIR-7831) for patients at high risk …
Thermo Fisher to acquire PPD in $17 billion deal
April 16, 2021Medical Communications thermo fisher
Medical device maker Thermo Fisher Scientific announced it would acquire contract research organisation PPD Inc for $17.4 billion, as it …
Gilead’s bladder cancer drug gets FDA approval
April 15, 2021FDA, Gilead, bladder cancer, bladder cancer treatment, pharma, pharma news
The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).
Roche’s Evrysdi drug for SMA shown to significantly increase survival
April 15, 2021PTC Therapeutics, Roche, pharma, pharma news, spinal muscular atrophy
Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) has been shown to increase …
First approved C5 complement inhibitor recommended by NICE for NHS use
April 15, 2021NHS, NICE
NICE has recommended Ultomiris (ravulizumab) for use in the NHS for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult …
Latest content
